House dust mite allergy vaccine injection - Alk-Abello

Drug Profile

House dust mite allergy vaccine injection - Alk-Abello

Alternative Names: Alutard; Alutard Der p; Alutard SQ; House dust mite SCIT - ALk-Abello; TO-204

Latest Information Update: 22 Dec 2015

Price : $50

At a glance

  • Originator ALK-Abello
  • Developer ALK-Abello; Eddingpharm; Torii Pharmaceutical
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Registered Allergic rhinitis

Most Recent Events

  • 24 Apr 2014 House dust mite allergy injection licensed to Eddingpharm China
  • 23 Dec 2013 Preregistration for Asthma and Allergic rhinitis in Japan (SC)
  • 01 Jul 2012 Phase-III clinical trials in Asthma and Allergic rhinitis in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top